Patients who moved from higher-dose injectable incretin therapies to Eli Lilly’s obesity pill Foundayo or to a lower dose of its injectable drug Zepbound were able to maintain most of their weight loss over time, according to results from two late-stage studies presented at the annual meeting of the European Congress on Obesity in Turkey.
The findings come from two Phase 3 programs evaluating maintenance strategies after initial weight reduction with incretin-based therapies. The results were presented alongside other obesity drug data from Lilly and Novo Nordisk, as both companies continue to develop treatments for weight loss and long-term maintenance use.
Lilly reported results from the Phase 3 ATTAIN-MAINTAIN study, which included more than 370 patients who had previously achieved weight loss using injectable incretin therapy. The study examined outcomes after switching to Foundayo, Lilly’s oral obesity drug.
Patients previously treated with Zepbound reduced their weight from an average of 115.8 kg (255 pounds) at the start of injectable treatment to 90.9 kg (198 pounds) before switching. After 52 weeks on Foundayo, average weight increased to 95.9 kg (211 pounds), indicating some regain but retention of most of the initial loss. Similar outcomes were reported for patients who transitioned from injectable Wegovy to Foundayo.
Lilly also released results from the Phase 3b SURMOUNT-MAINTAIN study, which assessed a lower 5-mg dose of Zepbound as a maintenance option after treatment with the highest tolerated doses of 10 mg or 15 mg. The study followed patients who had completed 60 weeks of maximum-dose treatment.
In the maintenance phase, patients who switched to the lower dose experienced slight weight regain but did not return to their starting weight. Participants went from an average of 196.2 pounds after maximum-dose treatment to around 208.6 pounds after 52 weeks on the lower dose.
Additional data previously released in December showed that patients regained about 5 kg (11 pounds) after switching from Zepbound to Foundayo and about 0.9 kg (2 pounds) after switching from Wegovy to Foundayo.
“Obesity is a chronic disease requiring long-term treatment, and patients need more options they can stay on for the long run,” said Kenneth Custer, Lilly’s executive vice president and president of cardiometabolic health.
He added that Lilly is committed to providing multiple treatment options as patients manage their weight-loss journey.
BMO Capital Markets commented on the results, stating that Foundayo could have an advantage in the maintenance setting, while noting that convenience may play a larger role once patients have already achieved weight loss.
Both Foundayo and oral Wegovy are taken once daily. However, Lilly’s drug does not require patients to avoid eating or drinking for 30 minutes after dosing, while oral Wegovy includes this restriction.
Novo Nordisk also presented new data on its obesity treatments, including injectable and oral Wegovy.
In a sub-analysis of the Step Up trial, about 27% of patients receiving the 7.2 mg injectable Wegovy dose lost at least 15% of their body weight within 24 weeks. Those patients reached nearly 28% average weight loss at week 72.
Novo also reported results from the Oasis 4 study of oral Wegovy. Nearly one-third of patients taking the 25 mg tablet lost an average of 13.2% of body weight after four months, with total mean weight loss reaching 21.6% by the end of the 64-week trial.
Novo additionally reported that nearly eight in 10 participants in a separate Oasis 4 analysis showed improvements in physical function, including activities such as standing for long periods and bending.
Foundayo Highlights Weight Loss Maintenance Results in Lilly Studies
Eli Lilly and Company released new study findings showing that patients maintained significant weight loss after switching to Foundayo or moving to lower-dose Zepbound treatment strategies. The research highlights growing interest in long-term obesity management solutions and personalized treatment approaches.
The latest findings suggest that Foundayo may help support sustainable weight management while potentially reducing the need for higher medication doses over time. Healthcare experts view the results as an important development in the rapidly expanding obesity treatment market.
Foundayo Supports Long-Term Obesity Treatment Strategies
The studies examined how patients responded after transitioning from higher-dose therapies to Foundayo or reduced-dose Zepbound regimens. Researchers observed encouraging outcomes related to maintaining weight reduction and treatment effectiveness.
As obesity continues to impact millions of people globally, pharmaceutical companies are focusing on therapies that not only promote initial weight loss but also help patients maintain long-term health improvements. Foundayo is gaining attention as part of this evolving treatment landscape.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
